Brought to you by 
Series C financing brings $38mm to GlycoMimetics
22 Oct 2009
Executive Summary
GlycoMimetics, which is developing small molecules with similar structures and activities to those of bioactive carbohydrates, has completed a $38mm Series C round. First-time backer Genzyme Ventures participated along with existing investors New Enterprise Associates, Novartis Venture Fund, Anthem Capital, and Alliance Technology Ventures. The money will fund a Phase II trial planned early next year for the company's lead compound GMI1070 in painful vaso-occlusive episodes associated with sickle cell disease, plus another Phase II study of the selectin antagonist in combination with chemotherapy for hematological cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C financing brings $38mm to GlycoMimetics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice